Table 2.
Metabolites with significant intensity level differences (<0.05) between control (n = 8) and fluoxetine (n = 8) groups in CSF.
| Metabolite | P-value | FC | FC-hiMAOA | FC-low-MAOA |
|---|---|---|---|---|
| N-Acetyl-D-glucosamine | 0.0088# | 1.19 | – | – |
| N1-Acetylspermidine | 0.0471 | – | 2.73 | 0.53 |
| Adenosine | 0.0088 | – | 0.36 | 2.21 |
| Adenosine monophosphate | 0.006 | – | 0.51 | 4.79 |
| Ascorbic acid | 0.024 | – | 0.48 | 1.64 |
| L-Asparagine | 0.0075 | – | 0.77 | 1.38 |
| L-Cystine | 0.0373 | – | 0.29 | 1.53 |
| Glyoxylic acid | 0.0427# | 1.35 | – | – |
| Guanosine | 0.012 | – | 0.83 | 2.94 |
| L-Homocysteic acid | 0.0469 | – | 0.52 | 1.03 |
| Homocysteine | 0.024 | – | 0.46 | 1.35 |
| L-Leucine | 0.0115 | – | 0.79 | 1.33 |
| L-Lysine | 0.0348 | – | 0.74 | 1.33 |
| L-Threonine | 0.0036 | – | 0.59 | 1.29 |
| Pantothenic acid | 0.039 | – | 1.94 | 0.75 |
| Pyruvic acid | 0.0135 | – | 0.95 | 1.44 |
FC: Fold change metabolite level of fluoxetine-treated relative to untreated control.
#
No interaction between treatment and genotype (one-way ANCOVA).